FRFrancesco Romano

Francesco Romano

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Francesco Romano has a total of 1000 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    FLASH radiotherapy for electrons and protons: roadmap towards the clinical introduction

    by Anna L Petoukhova, Sébastien Penninckx, Jan Schuemann, Fabio Di Martino, Fabiola Paiar, Anouk Sesink, Felipe A Calvo, Francesco Romano, Giuliana Milluzzo, Marco Schwarz, et al.

    Radiation therapy (RT) is a crucial component of cancer management, with most patients receiving RT at some point, often in combination with surgery or systemic treatments. Cell sparing at ultrahigh dose rates was found in in vitro cell survival fraction experiments dating back to the 1960s. In the 1970s, studies revealed an unexpected dose-rate effect on radiation-induced mortality in mice and a dose-rate-dependent response in rat skin. This effect was assumed to be affecting healthy and tumour tissue equally and was not pursued further. Decades later, this modality of RT was rediscovered using ultra-high dose-rate irradiation (average dose rate >40 Gy/s) and it was demonstrated that this improves the therapeutic ratio, sparing healthy tissue while being isoeffective for tumours. This effect is referred to as the FLASH effect. Currently, the first human trials using electron and proton beams are ongoing, although significant challenges remain in fully understanding the radiobiological and chemical mechanisms behind this phenomenon. This roadmap provides an overview of the current and future challenges of FLASH radiation therapy and outlines research directions to optimally advance the field and design future clinical trials: radiobiology of the FLASH effect, opportunities and beam parameters for the future in FLASH with electrons, intraoperative FLASH radiotherapy with electrons, ultra-high dose-rate dosimetry, opportunities for the future in FLASH with protons, FLASH treatment planning and machine QA with protons, clinical translation of FLASH with electrons and first experiences and challenges of initial proton FLASH trials.

  • Open Access

    Roadmap for the implementation of particle minibeam therapy

    by Reem Ahmad, Oxana Actis, Adam H. Aitkenhead, Richard A. Amos, Niels Bassler, Catherine Burne, Pankaj Chaudhary, Gerd Datzmann, Umberto Deut, Fabio Di Martino, et al.

    Particle minibeam therapy (PMBT) has emerged as an advanced modality within spatially fractionated radiation therapy, using the physical properties of protons, ions, and electrons to achieve superior normal tissue sparing whilst preserving spatial dose distribution at depths that are unachievable in conventional kV or MV X‐rays. As with any novel radiotherapy technique, successful translation into routine clinical practice requires robust evidence of efficacy, safety, and technical feasibility. This review presents a coordinated roadmap for the development and future implementation of PMBT, identifying the key challenges that must be addressed to enable safe and effective clinical implementation. This review highlights the interconnected nature of PMBT research and proposes the priority areas for future investigation, and the steps necessary to guide PMBT from experimental concept, towards clinical implementation. As most of the steps are relevant to all particle types, PMBT will be referred to in general, where specific particle types will be discussed where appropriate.

  • Open Access

    Evaluation of a simple graphite calorimeter for ultra‐high dose‐rate electron beam dosimetry

    by Anna Subiel, Alexandros Douralis, Graham Bass, David Shipley, Samuel Flynn, Francesco Romano, Giuliana Milluzzo, Fabio Di Martino, Damiano Del Sarto, Luigi Masturzo, et al.

    Objective. This study evaluates the performance of a simple secondary‐standard graphite calorimeter (SSCal) for absorbed‐dose measurements in ultra‐high dose‐rate (UHDR) electron beams, motivated by the need for reliable, traceable dosimetry for FLASH radiotherapy. Approach . The SSCal was calibrated against the primary absorbed‐dose standard at the National Physical Laboratory (NPL) and characterised in conventional 6-10 MeV electron beams. Monte Carlo (MC) simulations were used to derive detector‐specific perturbation and field‐size correction factors, including conversion from absorbed dose to graphite to absorbed dose to water. The SSCal was then tested in a 9 MeV UHDR beam (0.06–5.78 Gy pulse −1 ) at the Centro Pisano Flash Radiotherapy facility. Absorbed dose was determined using two independent approaches: (1) application of the calibration coefficient derived experimentally at NPL, and (2) first‐principles calorimetry. Alanine dosimetry provided an independent traceability route for cross‐validation. Main results . Calibration coefficients obtained at NPL showed minimal dependence on field size or beam quality. MC simulations indicated that perturbations were dominated by internal air gaps, with increasing magnitude at small field sizes. Corresponding beam quality correction factors enabled accurate application of the NPL calibration to the UHDR beam. Across all dose-per-pulse (DPP) values, the two dose determination methods agreed within 1%. The SSCal exhibited excellent linearity with pulse number and stable response for three pulses or more. A systematic Δ T /MU trend was observed only for single- or double-pulse exposures, for which transient perturbations in the beam current transformer signal provide a plausible explanation. In addition, or alternatively, the observed reduction in detector response may be influenced by non-linear heat-transfer effects within the calorimeter, potentially associated with cumulative heating and delayed thermistor equilibration. Agreement between SSCal and alanine was within ±1% for all but the highest DPP (5.71 Gy pulse −1 ), where a 2.6% deviation was observed under low-pulse conditions, which is consistent with the Δ T /MU trend. Significance . The results demonstrate that the SSCal provides stable, linear, and largely dose‐rate‐independent absorbed‐dose measurements in UHDR electron beams when appropriate MC‐derived corrections are applied, while indicating that a potential deviation from ideal response cannot be excluded at the highest investigated DPP values (>5 Gy pulse −1 ). These findings support suitability of SSCal as a reference-quality dosimeter for FLASH research and development.


  • Open Access

    Dosimetric characterization of an encapsulated waterproof silicon carbide detector with UHDR electron and proton beams for FLASH radiotherapy

    by G Milluzzo, D Zitelli, A Cavalieri, M Celentano, F Di Martino, L Masturzo, C Okpuwe, J H Pensavalle, S Lorentini, E Scifoni, et al.

    Silicon carbide (SiC) detectors have been widely demonstrated to be suitable alternative detectors for dosimetry in FLASH radiotherapy, showing radiation hardness and dose-rate independence at the FLASH radiotherapy instantaneous dose rates (IDRs). However, the practical use of such devices in the preclinical/clinical environment still requires the development of special handy housing enabling the quality assurance (QA) measurements under the reference dosimetric conditions. A 10 μm thick, 4.5 mm2 area SiC detector produced by the STLab company was recently embedded at the INFN-Catania Division inside a plastic waterproof 15 mm diameter cylindrical housing. This encapsulated version of SiC (eSiC) allows the measurement of the dose in reference conditions and of the dose profiles in liquid/solid water phantoms for assuring high accuracy dosimetry QA procedures. Dosimetric characterizations were performed with both electron and proton beams at conventional and ultra-high dose rates (UHDR). A first experiment was carried out at the Centro Pisano for Flash Radiotherapy using UHDR 9 MeV electron beams to confirm the linearity of the charge response as a function of the dose per pulse after the encapsulation procedure. A linearity from 1.8 Gy/pulse up to about 12 Gy/pulse, corresponding to an IDR of 3 MGy s−1, was found. The percentage depth dose (PDD) distribution in water of 9 MeV electron beams was also measured and compared with the PDD measured with a Freiburg Physikalisch-Technische Werkstätten Dr. Pychlau GmbH (PTW) flash diamond detector, used as reference dosimeter. The eSiC detector was also tested with proton beams accelerated by the IBA Proteus 235 cyclotron at the Trento Proton Therapy facility. A response independence on the total delivered dose (1–30 Gy) and average dose rate (50–530 Gy s−1) was found using the UHDR 228 MeV proton beam available along the experimental beamline. The depth dose distribution measured with the eSiC within a liquid water phantom was successfully compared with the one simultaneously measured by the IBA PPC05 reference chamber, using 180 MeV clinical proton beams. The excellent results demonstrated that this first realized eSiC prototype can be used to accurately perform reference and relative dosimetry with UHDR electron and proton beams, contributing to support the clinical translation of FLASH radiotherapy.


  • Top Cited Papers
    Open Access

    Results of a Geant4 benchmarking study for bio‐medical applications, performed with the G4‐Med system

    by Pedro Arce, Jay W. Archer, Lorenzo Arsini, Alexander Bagulya, David Bolst, Jeremy M. C. Brown, Barbara Caccia, Andrew Chacon, Giuseppe Antonio Pablo Cirrone, Miguel Antonio Cortés‐Giraldo, et al.

    Background: Geant4, a Monte Carlo Simulation Toolkit extensively used in bio‐medical physics, is in continuous evolution to include newest research findings to improve its accuracy and to respond to the evolving needs of a very diverse user community. In 2014, the G4‐Med benchmarking system was born from the effort of the Geant4 Medical Simulation Benchmarking Group, to benchmark and monitor the evolution of Geant4 for medical physics applications. The G4‐Med system was first described in our Medical Physics Special Report published in 2021. Results of the tests were reported for Geant4 10.5. Purpose: In this work, we describe the evolution of the G4‐Med benchmarking system. Methods: The G4‐Med benchmarking suite currently includes 23 tests, which benchmark Geant4 from the calculation of basic physical quantities to the simulation of more clinically relevant set‐ups. New tests concern the benchmarking of Geant4‐DNA physics and chemistry components for regression testing purposes, dosimetry for brachytherapy with a source, dosimetry for external x‐ray and electron FLASH radiotherapy, experimental microdosimetry for proton therapy, and in vivo PET for carbon and oxygen beams. Regression testing has been performed between Geant4 10.5 and 11.1. Finally, a simple Geant4 simulation has been developed and used to compare Geant4 EM physics constructors and physics lists in terms of execution times. Results: In summary, our EM tests show that the parameters of the multiple scattering in the Geant4 EM constructor G4EmStandardPhysics_option3 in Geant4 11.1, while improving the modeling of the electron backscattering in high atomic number targets, are not adequate for dosimetry for clinical x‐ray and electron beams. Therefore, these parameters have been reverted back to those of Geant4 10.5 in Geant4 11.2.1. The x‐ray radiotherapy test shows significant differences in the modeling of the bremsstrahlung process, especially between G4EmPenelopePhysics and the other constructors under study ( G4EmLivermorePhysics , G4EmStandardPhysics_option3 , and G4EmStandardPhysics_option4 ). These differences will be studied in an in‐depth investigation within our Group. Improvement in Geant4 11.1 has been observed for the modeling of the proton and carbon ion Bragg peak with energies of clinical interest, thanks to the adoption of ICRU90 to calculate the low energy proton stopping powers in water and of the Linhard–Sorensen ion model, available in Geant4 since version 11.0. Nuclear fragmentation tests of interest for carbon ion therapy show differences between Geant4 10.5 and 11.1 in terms of fragment yields. In particular, a higher production of boron fragments is observed with Geant4 11.1, leading to a better agreement with reference data for this fragment. Conclusions: Based on the overall results of our tests, we recommend to use G4EmStandardPhysics_option4 as EM constructor and QGSP_BIC_HP with G4EmStandardPhysics_option4 , for hadrontherapy applications. The Geant4‐DNA physics lists report differences in modeling electron interactions in water, however, the tests have a pure regression testing purpose so no recommendation can be formulated.


  • CHARACTERISATION OF SATURATION AND POLARISATION OF DIFFERENT IONISATION CHAMBERS WORKING IN FLASH REGIMEN

    by L. Masturzo, S. Capaccioli, D. Del Sarto, G. Felici, G. Milluzzo, M. Montefiori, F. Paiar, J. Pensavalle, F. Romano, S. Rossomme, et al.

  • FRONTIER SOLID-STATE TECHNOLOGIES: A POSSIBLE ACE UP YOUR SLEEVE FOR FLASH BEAM MONITORING?

    by A. Vignati, M. Abujami, M. Camarda, C. Galeone, S. Giordanengo, O. Martì Villarreal, F. Mas Milian, F. Romano, F. Picollo, R. Sacchi, et al.

  • FLASH Modalities Track (Oral Presentations) CALORIMETRY FOR ULTRA-HIGH-DOSE-RATE VERY HIGH ENERGY ELECTRON BEAMS

    by M. Mcmanus, F. Romano, G. Royle, W. Farabolini, A. Gilardi, H. Palmans

  • Top Cited Papers
    Open Access

    First experimental proof of Proton Boron Capture Therapy (PBCT) to enhance protontherapy effectiveness

    by G. A. P. Cirrone, L. Manti, D. Margarone, G. Petringa, L. Giuffrida, A. Minopoli, A. Picciotto, G. Russo, F. Cammarata, P. Pisciotta, et al.

    Protontherapy is hadrontherapy’s fastest-growing modality and a pillar in the battle against cancer. Hadrontherapy’s superiority lies in its inverted depth-dose profile, hence tumour-confined irradiation. Protons, however, lack distinct radiobiological advantages over photons or electrons. Higher LET (Linear Energy Transfer) 12C-ions can overcome cancer radioresistance: DNA lesion complexity increases with LET, resulting in efficient cell killing, i.e. higher Relative Biological Effectiveness (RBE). However, economic and radiobiological issues hamper 12C-ion clinical amenability. Thus, enhancing proton RBE is desirable. To this end, we exploited the p + 11B → 3α reaction to generate high-LET alpha particles with a clinical proton beam. To maximize the reaction rate, we used sodium borocaptate (BSH) with natural boron content. Boron-Neutron Capture Therapy (BNCT) uses 10B-enriched BSH for neutron irradiation-triggered alpha particles. We recorded significantly increased cellular lethality and chromosome aberration complexity. A strategy combining protontherapy’s ballistic precision with the higher RBE promised by BNCT and 12C-ion therapy is thus demonstrated.